New MenaQ7 patents granted to NattoPharma in US, Israel and Australia

6b8015c8-ad96-4c8c-a133-ab76615dc355articleimage.jpg

08 Nov 2017 --- NattoPharma ASA has successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

“These patents underline our position as the leader in the vitamin K2 market,” Kjetil Ramsøy, NattoPharma Chief Financial Officer, tells NutritionInsight. “Having the most clinically validated vitamin K2 as MK-7 available today, and the only all-trans nature-identical synthetic available that is free of cis-isomers, this will give our partners the validation they need to ensure they are serving their customers the best possible product.”

Global success with patents
NattoPharma details the company’s progress with patents:

  • Israel: On July 31, 2017, patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
  • US: On August 28, 2017, Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
  • Australia: On July 5, 2017, Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2.” This NoA was published on July 20.

“This unique patented process results in the world’s only truly all-trans synthetic vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. “Our material is of the highest quality and superior to anything else on the market, so much so that it is currently being utilized in two studies sponsored by the traditional medical community.”

“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits,” he continues. “This technology also ensures supplement providers deliver the MK-7 with the health benefits consumers desire.”

Sommer adds that NattoPharma has made significant intellectual and monetary investments technologies in, and that the company is committed to actively monitor market developments to protect the company’s intellectual property rights throughout their lifespan.

“The approval of these patents represents another milestone for NattoPharma and our partners,” concludes Sommer. “This further strengthens NattoPharma’s global intellectual property rights platform and improves our competitive position within the food supplement market.”

“We see a very positive development in the interest in vitamin K2, which is also supported by our global growth over the last couple of years,” Ramsøy notes to NutritionInsight. “We expect this to continue in the coming years as the knowledge about the benefits of Vitamin K2 grows even more in the consumer market.”

There are also plans to obtain patents for MenaQ7 in further countries. “Patents are currently pending in a number of different jurisdictions, both for the synthetic production patent for PharmaPure, as well as for different health claims related to the use of vitamin K2 as a dietary supplement,” Ramsøy explains.

By Paul Creasy

Related Articles

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

Ultra-processed foods linked to heightened risk of cancer: major BMJ study

15 Feb 2018 --- Although processed foods have long been thought to be significantly less healthy than non-processed foods, an observational study published yesterday in BMJ has added some stark figures to the link between ultra-processed foods and the risk of cancer. The study concluded that a 10 percent increase in the proportion of ultra-processed foods in the diet is associated with increases of 12 percent in the risk of overall cancer and 11 percent in the risk of breast cancer.

Business News

Natures Crops, De Wit Speciality Oils enter into European distribution partnership for Ahiflower oil

15 Feb 2018 --- Natures Crops International and De Wit Speciality Oils have entered into a distribution agreement for Ahiflower oil in the European dietary supplement marketplace. This alliance is thought to add strategic value for both companies through each company’s leading position in manufacturing and marketing nutraceutical products.

Nutrition & Health News

Façade? British Nutrition Foundation questions benefit of skin beauty nutraceuticals

14 Feb 2018 --- Although there is a growing market for orally consumed beauty supplements that promise “youthful,” “firm” and “glowing” skin, the evidence to support some of the ingredients used in these popular, and often costly, products is limited. This is according to a review of published research conducted by the British Nutrition Foundation (BNF). The review concludes that nutraceuticals for skin may not add further benefit to the effects already obtained from a healthy diet. 

Nutrition & Health News

A gold medal for recovery? FrieslandCampina DMV develops innovative casein isolate 

14 Feb 2018 --- FrieslandCampina DMV has introduced their latest innovation in dairy protein ingredients. Micelate Prestige has been launched this week in Europe and is a key addition to the company’s growing portfolio of Performance Nutrition solutions. 

More Articles
URL : http://www.nutritioninsight.com:80/news/new-menaq7-patents-granted-to-nattopharma-in-us-israel-and-australia.html